Evidence map›Paper›PMID 37468732›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2023

Impact of preoperative chemotherapy on perioperative morbidity in combined resection of colon cancer and liver metastases.

Joy Z Done, Angelos Papanikolaou, Miloslawa Stem, Shannon N Radomski, Sophia Y Chen, Chady Atallah, Jonathan E Efron, Bashar Safar

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joy Z DoneColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.ORCID 0000-0001-8992-8179
Angelos PapanikolaouColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Miloslawa StemColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Shannon N RadomskiColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Sophia Y ChenColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Chady AtallahColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Jonathan E EfronColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA.
Bashar SafarColorectal Research Unit, Department of Surgery, Johns Hopkins University, Baltimore, USA. Bashar.Safar@nyulangone.org.
Johns Hopkins University · US

Funding

Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Division of Cancer Epidemiology and Genetics, National Cancer Institute 5T32CA126607-12
6 · The paper itself

Abstract

backgroundPreoperative chemotherapy, or neoadjuvant therapy (NAC) can be used to improve resectability but can also have hepatotoxic effects on the future liver remnant. The purpose of this study was to investigate the impact of NAC on 30-day morbidity among patients undergoing a resection of primary colon cancer and synchronous liver metastases (sLM).

methodsThis was a retrospective study using the National Surgical Quality Improvement Program database (2012-2020). The association between NAC and 30-day overall morbidity, the primary outcome, was assessed. Subgroup analyses for low and high-risk procedures were performed.

resultsAmong 968 patients who underwent the combined resection, 571 (58.99%) received NAC. There was a lower rate of 30-day overall morbidity among patients who received NAC (34.50% vs. 41.56%, p = 0.026) and no difference in rates of postoperative liver failure, bile leak, need for invasive intervention for hepatic procedure, and anastomotic leak. On adjusted analyses, patients who received NAC had decreased odds of overall morbidity (OR 0.73, 95% CI 0.55-0.97, p = 0.031) compared to patients who did not receive NAC. On subgroup analyses, patients who received NAC prior to a low risk combined resection had lower rates of overall morbidity on both adjusted and unadjusted analyses. Among those undergoing high-risk combined resections, there was no difference in overall morbidity. DISCUSSION AND

conclusionPatients who are deemed to be candidates for preoperative chemotherapy can proceed with planned neoadjuvant chemotherapy prior to combined resection of primary colon cancer and sLM as preoperative neoadjuvant chemotherapy does not appear to be associated with increased postoperative morbidity.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsLiver NeoplasmsHepatectomyHumansMorbidityNeoadjuvant TherapyRetrospective StudiesColon cancerColorectal liver metastasesNeoadjuvant chemotherapyNSQIPSimultaneous resectionSynchronous liver metastases

Identifiers

PMID37468732
OpenAlexW4384820751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.